NO20042575L - Fremgangsmate for vat granulering av azithromycin - Google Patents

Fremgangsmate for vat granulering av azithromycin

Info

Publication number: NO20042575L
Authority: NO; Norway
Prior art keywords: azithromycin; procedure; aqueous granulation; granulation; aqueous
Prior art date: 2001-12-21

Application number

NO20042575A

Other languages

English (en)

Inventor

Michael Bruce Fergione

Barbara Alice Johnson

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-21

Filing date

2004-06-18

Publication date

2004-06-18

2004-06-18 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-06-18 Publication of NO20042575L publication Critical patent/NO20042575L/no

Links

MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title 1
229960004099 azithromycin Drugs 0.000 title 1
238000005469 granulation Methods 0.000 title 1
230000003179 granulation Effects 0.000 title 1
238000000034 method Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)

NO20042575A 2001-12-21 2004-06-18 Fremgangsmate for vat granulering av azithromycin NO20042575L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34346901P	2001-12-21	2001-12-21
PCT/IB2002/005338 WO2003053399A2 (en)	2001-12-21	2002-12-09	Methods for wet granulating azithromycin

Publications (1)

Publication Number	Publication Date
NO20042575L true NO20042575L (no)	2004-06-18

Family

ID=23346249

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20042575A NO20042575L (no)	2001-12-21	2004-06-18	Fremgangsmate for vat granulering av azithromycin

Country Status (21)

Country	Link
US (1)	US20030190365A1 (no)
EP (1)	EP1455757A2 (no)
JP (1)	JP2005515212A (no)
KR (1)	KR100669279B1 (no)
CN (1)	CN1606433A (no)
AR (1)	AR037931A1 (no)
AU (1)	AU2002353316A1 (no)
BR (1)	BR0215175A (no)
CA (1)	CA2470055A1 (no)
HN (1)	HN2002000376A (no)
IL (1)	IL161259A0 (no)
MX (1)	MXPA04003027A (no)
NO (1)	NO20042575L (no)
NZ (1)	NZ532063A (no)
PA (1)	PA8562101A1 (no)
PE (1)	PE20030588A1 (no)
PL (1)	PL371125A1 (no)
RU (1)	RU2283651C2 (no)
TW (1)	TW200301260A (no)
WO (1)	WO2003053399A2 (no)
ZA (1)	ZA200402586B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20020231A2 (en)	2002-03-18	2003-12-31	Pliva D D	ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
IL161996A0 (en) *	2001-12-21	2005-11-20	Pfizer Prod Inc	Directly compressible formulations of azithromycin
HRP20020614A2 (en) *	2002-07-22	2004-06-30	PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o.	Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
WO2005002592A2 (en) *	2003-07-01	2005-01-13	Ranbaxy Laboratories Limited	Stable oral compositions of azithromycin monohydrate
JP2007513139A (ja)	2003-12-04	2007-05-24	ファイザー・プロダクツ・インク	安定性の改善した多粒子組成物
CA2549225A1 (en)	2003-12-04	2005-06-16	Pfizer Products Inc.	Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
JP2007513145A (ja)	2003-12-04	2007-05-24	ファイザー・プロダクツ・インク	医薬用多微粒子の製造方法
US6984403B2 (en) *	2003-12-04	2006-01-10	Pfizer Inc.	Azithromycin dosage forms with reduced side effects
WO2005053652A1 (en)	2003-12-04	2005-06-16	Pfizer Products Inc.	Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
US7943585B2 (en)	2003-12-22	2011-05-17	Sandoz, Inc.	Extended release antibiotic composition
KR20060129303A (ko) *	2003-12-23	2006-12-15	템렐 리미티드	약제학적 조성물을 위한 펠렛을 생산하는 방법
US7468428B2 (en)	2004-03-17	2008-12-23	App Pharmaceuticals, Llc	Lyophilized azithromycin formulation
UA95093C2 (uk) *	2005-12-07	2011-07-11	Нікомед Фарма Ас	Спосіб одержання кальцієвмісної сполуки
CN100441196C (zh) *	2006-12-15	2008-12-10	北京化工大学	一种制备微粉化阿奇霉素的方法
GB0715628D0 (en) *	2007-08-10	2007-09-19	Generics Uk Ltd	Solid valsartan composition
CA2744377A1 (en) *	2008-11-20	2010-05-27	Avantor Performance Materials, Inc.	Directly compressible high functionality granular dibasic calcium phosphate based co-processed excipient
US8106111B2 (en)	2009-05-15	2012-01-31	Eastman Chemical Company	Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
RU2403049C1 (ru) *	2009-06-04	2010-11-10	Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова Федерального агентства по здравоохранению и социальному развитию (ГОУВПО ММА им. И.М. Сеченова Росздрава)	Способ получения таблеток эритромицина
EP2295037A1 (en) *	2009-09-11	2011-03-16	Ratiopharm GmbH	Pharmaceutical formulation containing Ribavirin
RU2480689C1 (ru) *	2011-10-26	2013-04-27	Александр Михайлович Муртищев	Способ получения порошкообразных продуктов
DK3378479T3 (da) *	2016-01-27	2020-08-03	Jiangsu Hengrui Medicine Co	Fremgangsmåde til forberedelse af farmakologisk sammensætning, der omfatter qionolinderivat eller salt deraf
WO2017163170A1 (en) *	2016-03-21	2017-09-28	Sun Pharmaceutical Industries Limited	Pharmaceutical composition comprising apixaban
CN110292567B (zh) *	2019-05-17	2022-02-18	北京悦康科创医药科技股份有限公司	一种阿奇霉素胶囊的制备方法
CN113088422A (zh) *	2021-05-18	2021-07-09	耿艳飞	一种荞麦果醋
CN113559073A (zh) *	2021-07-20	2021-10-29	海南海神同洲制药有限公司	阿奇霉素片剂及其制备方法
CN116930013A (zh) *	2023-07-28	2023-10-24	海南卫康制药(潜山)有限公司	一种阿奇霉素干混悬剂中原料粒度的测定方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4474768A (en) *	1982-07-19	1984-10-02	Pfizer Inc.	N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RO107257B1 (ro) *	1987-07-09	1993-10-30	Pfizer	Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (en) *	1987-09-10	1989-03-23	Pfizer	Azithromycin and derivatives as antiprotozoal agents
TW271400B (no) *	1992-07-30	1996-03-01	Pfizer
US5605889A (en) *	1994-04-29	1997-02-25	Pfizer Inc.	Method of administering azithromycin
EP0758244B2 (en) *	1994-05-06	2008-02-13	Pfizer Inc.	Controlled-release dosage forms of azithromycin
DE19706978A1 (de) *	1997-02-21	1998-08-27	Ulrich Dr Posanski	Kombinationspräparat für oral applizierbare Antibiotika
US6339063B1 (en) *	1997-09-10	2002-01-15	Merck & Co., Inc.	9a-azalides as veterinary antimicrobial agents
CA2245398C (en) *	1998-08-21	2002-01-29	Apotex Inc.	Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
JP2002531409A (ja) *	1998-11-30	2002-09-24	テバファーマシューティカルインダストリーズリミティド	アジスロマイシンのエタノール付加物、その製造方法、及びその医薬製剤
ATE469910T1 (de) *	1999-06-29	2010-06-15	Sandoz Ag	Azithromycinmonohydrat
IL158591A0 (en) *	2001-05-22	2004-05-12	Pfizer Prod Inc	Crystal forms of azithromycin
US6764997B2 (en) *	2001-10-18	2004-07-20	Teva Pharmaceutical Industries Ltd.	Stabilized azithromycin compositions

2002
- 2002-12-09 EP EP02788337A patent/EP1455757A2/en not_active Withdrawn
- 2002-12-09 KR KR1020047009808A patent/KR100669279B1/ko not_active Expired - Fee Related
- 2002-12-09 PL PL02371125A patent/PL371125A1/xx not_active Application Discontinuation
- 2002-12-09 NZ NZ532063A patent/NZ532063A/xx unknown
- 2002-12-09 IL IL16125902A patent/IL161259A0/xx unknown
- 2002-12-09 AU AU2002353316A patent/AU2002353316A1/en not_active Abandoned
- 2002-12-09 WO PCT/IB2002/005338 patent/WO2003053399A2/en not_active Ceased
- 2002-12-09 JP JP2003554158A patent/JP2005515212A/ja not_active Withdrawn
- 2002-12-09 MX MXPA04003027A patent/MXPA04003027A/es unknown
- 2002-12-09 CN CNA02825788XA patent/CN1606433A/zh active Pending
- 2002-12-09 BR BR0215175-8A patent/BR0215175A/pt not_active IP Right Cessation
- 2002-12-09 CA CA002470055A patent/CA2470055A1/en not_active Abandoned
- 2002-12-09 RU RU2004118502/15A patent/RU2283651C2/ru not_active IP Right Cessation
- 2002-12-13 PE PE2002001222A patent/PE20030588A1/es not_active Application Discontinuation
- 2002-12-19 HN HN2002000376A patent/HN2002000376A/es unknown
- 2002-12-19 AR ARP020105017A patent/AR037931A1/es unknown
- 2002-12-20 US US10/327,383 patent/US20030190365A1/en not_active Abandoned
- 2002-12-20 PA PA20028562101A patent/PA8562101A1/es unknown
- 2002-12-20 TW TW091136906A patent/TW200301260A/zh unknown
2004
- 2004-04-01 ZA ZA200402586A patent/ZA200402586B/en unknown
- 2004-06-18 NO NO20042575A patent/NO20042575L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NZ532063A (en)	2006-03-31
WO2003053399A3 (en)	2004-05-21
PE20030588A1 (es)	2003-07-08
IL161259A0 (en)	2004-09-27
CN1606433A (zh)	2005-04-13
MXPA04003027A (es)	2004-07-05
CA2470055A1 (en)	2003-07-03
PL371125A1 (en)	2005-06-13
AU2002353316A1 (en)	2003-07-09
AR037931A1 (es)	2004-12-22
TW200301260A (en)	2003-07-01
BR0215175A (pt)	2004-12-28
RU2283651C2 (ru)	2006-09-20
JP2005515212A (ja)	2005-05-26
WO2003053399A2 (en)	2003-07-03
ZA200402586B (en)	2005-04-01
KR20040073504A (ko)	2004-08-19
US20030190365A1 (en)	2003-10-09
KR100669279B1 (ko)	2007-01-16
HN2002000376A (es)	2003-02-21
RU2004118502A (ru)	2005-04-10
EP1455757A2 (en)	2004-09-15
PA8562101A1 (es)	2005-02-04

Legal Events

Date	Code	Title	Description
2009-07-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20042680L (no)	2004-06-25	Fremgangsmater for fremstilling av O-demetylvenflaxine
NO20035177D0 (no)	2003-11-21	Krystallformer av Azithromycin
NO20043110L (no)	2004-07-20	Direkte komprimerbare formuleringer av azitromycin
NO20035522D0 (no)	2003-12-11	Kinuklidin-substituerte multisykliske heteroaryler for behandling av sykdom
NO20030012L (no)	2003-03-03	Fremgangsmåte for fremstilling av substituerte oktanoylamider
NO20040027L (no)	2004-01-05	Fremgangsmate for fremstillingen av escitalopram
NO20023549D0 (no)	2002-07-25	Fremgangsmåte for rensing av 1,2-dikloretan
NO20040292L (no)	2004-03-19	Fremgangsmate for fremstilling av 4-aminodifenylamin
FI20011541A0 (fi)	2001-07-13	Menetelmä massan valmistamiseksi
NO20040278L (no)	2004-01-21	Fremgangsmate for fremstilling av perindopril
NO20032731D0 (no)	2003-06-16	Fremgangsmåte for fremstilling av sulfonamid-substituerte imidazotriazinoner
FI20012170A0 (fi)	2001-11-09	Menetelmä lauhteiden käsittelemiseksi
NO20042640L (no)	2004-06-23	Fremgangsmate for fremstilling av ekinocandinderivater
NO20023445L (no)	2003-01-20	Fremgangsmåte for fremstilling av peptider
NO20030515L (no)	2003-03-31	Fremgangsmåte for fremstilling av dinapsolin
NO20035586D0 (no)	2003-12-15	Fremgangsmåte for fremstilling av cykloheksanol-derivater
NO20031927L (no)	2003-04-29	Forbedret fremgangsmåte for fremstilling av gabapentinmellomprodukt
NO20035138D0 (no)	2003-11-18	Fremgangsmåte til fremstilling av amorft natriumsilastatin
NO20041193L (no)	2004-03-22	Fremgangsmåte til fremstilling av beta-ionylidenacetaldehyd
NO20023702D0 (no)	2002-08-06	Fremgangsmåte for fremstilling av 5-arylnikotinaldehyder
FI20012552A0 (fi)	2001-12-21	Metallikarbonaatin valmistusmenetelmä
NO20034972L (no)	2003-11-07	Behandling av ADHD
NO20010171D0 (no)	2001-01-11	Teknisk behandling av tåke
NO20013802D0 (no)	2001-08-02	Fremgangsmåte for fremstilling av kitosaner
NO20035273D0 (no)	2003-11-27	Fremgangsmåte for fremstilling av 3-aryl-2- hydroksypropionsyrederivater